Day One Biopharmaceuticals, Inc.
DAWNDelisted- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001845337
Day One Biopharmaceuticals, Inc. was delisted in 2026; its insiders filed their last Form 4 on Apr 27, 2026; 208 institutions reported holding it in 13F filings for Q1 2026, worth $1.85B in total; Soros Fund Management was the only superinvestor holding it.
Key figures
- Insider buys
- 0
- Open market, last 90 days
- Insider sells
- 0
- Open market, last 90 days
- 13F holders
- 208
- Q1 2026, +28 vs. previous quarter
- 13F value
- $1.85B
- Reported value at the end of Q1 2026
- Superinvestors holding
- 1
- At the end of Q1 2026
Superinvestors holding DAWN, Q1 2026
1 superinvestor reports holding Day One Biopharmaceuticals, Inc. on Form 13F. Percentages are the stock's share of each portfolio.
Soros Fund Management
George Soros
0.5%
Day One Biopharmaceuticals, Inc.'s share of the portfolio
- Shares
- 1,539,100
- Value
- $33.0M
Latest insider trades
Open-market purchases and sales by Day One Biopharmaceuticals, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Feb 18, 2026 (view filing) | Feb 17 | 1 day | Bender JeremyCHIEF EXECUTIVE OFFICER | SSale | −15.5K | $11.60 | −$179.3K | −7.0%204.6K after | |
| Feb 18, 2026 (view filing) | Feb 17 | 1 day | Merendino LaurenChief Commercial Officer | SSale | −5.81K | $11.60 | −$67.4K | −8.8%60.2K after | |
| Feb 18, 2026 (view filing) | Feb 17 | 1 day | Dubow AdamGen Counsel & Secretary | SSale | −6.39K | $11.60 | −$74.2K | −8.1%72.7K after | |
| Feb 18, 2026 (view filing) | Feb 17 | 1 day | Vasconcelles MichaelHead of Research and Dev. | SSale | −2.73K | $11.60 | −$31.6K | −38.3%4.40K after | |
| Feb 18, 2026 (view filing) | Feb 17 | 1 day | York Charles N IICOO and CFO | SSale | −6.07K | $11.60 | −$70.4K | −1.9%312.0K after | |
| Nov 18, 2025 (view filing) | Nov 17 | 1 day | Bender JeremyCHIEF EXECUTIVE OFFICER | SSale | −15.9K | $8.91 | −$141.6K | −8.2%177.2K after | |
| Nov 18, 2025 (view filing) | Nov 17 | 1 day | Merendino LaurenChief Commercial Officer | SSale | −3.73K | $8.91 | −$33.2K | −6.8%50.8K after | |
| Nov 18, 2025 (view filing) | Nov 17 | 1 day | Dubow AdamGen Counsel & Secretary | SSale | −4.32K | $8.91 | −$38.5K | −6.5%62.6K after | |
| Nov 18, 2025 (view filing) | Nov 17 | 1 day | York Charles N IICOO and CFO | SSale | −4.06K | $8.91 | −$36.2K | −1.4%294.7K after | |
| Aug 19, 2025 (view filing) | Aug 18 | 1 day | York Charles N IICOO and CFO | SSale | −4.11K | $6.77 | −$27.8K | −1.5%278.0K after |
Top 10 13F holders, Q1 2026
The largest institutional positions in Day One Biopharmaceuticals, Inc. at the end of Q1 2026; share changes are against Q4 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| BlackRock, Inc. | 7,044,487 | $151.0M | 0.00% | −1,793,087−20.3% | Reduced |
| Glazer Capital, LLC | 4,683,687 | $100.4M | 2.13% | +4,683,687 | New |
| FIL Ltd | 4,131,907 | $88.6M | 0.07% | +4,131,907 | New |
| Kryger Capital LLC | 3,896,485 | $83.5M | 5.91% | +3,896,485 | New |
| Deerfield Management Company, L.P. (Series C) | 3,723,131 | $79.8M | 0.94% | 00.0% | Unchanged |
| Vanguard Capital Management LLC | 3,357,684 | $72.0M | 0.00% | +3,357,684 | New |
| JPMorgan Chase & Co | 3,134,753 | $67.1M | 0.00% | +3,091,223+7,101.4% | Added |
| State Street Corp | 2,869,876 | $61.5M | 0.00% | −1,419,690−33.1% | Reduced |
| Balyasny Asset Management LLC | 2,625,235 | $56.3M | 0.11% | +1,135,311+76.2% | Added |
| CNH Partners LLC | 2,462,154 | $52.8M | 0.87% | +2,462,154 | New |